Deans' stroke musings: IBM, Pfizer team on remote monitoring for Parkinson’s care

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Friday, April 8, 2016

IBM, Pfizer team on remote monitoring for Parkinson’s care - Why not stroke?

If our fucking failures of stroke associations actually wanted to help survivors they would be partnering with Dr. Watson/IBM to objectively monitor survivor movements so our therapists could then apply the correct stroke protocols to correct those deficits. Yes, this is totally pie in the sky, but much better to at least try something rather than the lazy press releases and prevention ideas.
It should be simple to attach monitors registering position and movement to appropriate joints and muscles on the body sending signals to the smartphone app collecting such data. Such monitors are already in Fitbits.
http://medcitynews.com/2016/04/ibm-pfizer-remote-monitoring-parkinsons/?
Watson Health may be getting all the headlines lately, but IBM’s research division is busy trying to improve healthcare as well. Thursday, Big Blue announced that it was collaborating with Pfizer to develop remote monitoring technology for treating Parkinson’s disease.
IBM and Pfizer will build an Internet-of-Things ecosystem to measure the health and quality of life of Parkinson’s patients. They want data collection to be as continuous and unobtrusive to the patient as possible.
Their sensors will gather real-time information from patients outside of a clinical environment. Then, IBM will apply machine learning to the data to help researchers advance their understanding of the disease and treatments.
“The problem in the field of chronic neurological diseases like Parkinson’s is that the symptoms that the patient experiences vary minute by minute,” Ajay Royyuru, director of healthcare and life sciences for IBM Research, said in a video supplied by the two companies. “You pretty much have to monitor the symptoms that the individual is having pretty much on a continuous basis.”
“We have an opportunity to potentially redefine how we think about patient outcomes and 24/7 monitoring, by combining Pfizer’s scientific, medical and regulatory expertise with IBM’s ability to integrate and interpret complex data in innovative ways,” Pfizer global R&D head Dr. Mikael Dolsten said in a statement.
“The key to our success will be to deliver a reliable, scalable system of measurement and analysis that would help inform our clinical programs across important areas of unmet medical need, potentially accelerating the drug development and regulatory approval processes and helping us to get better therapies to patients, faster,” Dolsten added.